Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06463860 · ClinicalTrials.gov registry record
Multi-Center Study to Evaluate the Performance of DermDx for Primary Care Physicians in the Detection of Skin Cancers
A clinical trial of Skin Cancer, sponsored by MetaOptima Technology.
- Completed
- Registry status
- 81
- Enrollment target
- 1
- Study location
NCT06463860: Completed study of Skin Cancer, sponsored by MetaOptima Technology.
NCT06463860 is a study of Skin Cancer that has completed, run by MetaOptima Technology. The registered enrollment target is 81 participants, below the 462-participant average among 40 other Skin Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06463860, a study of Skin Cancer, has completed, sponsored by MetaOptima Technology.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is a pivotal, multi-center retrospective reader study designed to determine whether the use of DermDx as a concurrent reading aid improves the performance of primary care physicians (PCPs) in diagnosing skin cancers.
Primary Outcome
The change in the diagnostic sensitivity of the PCPs with the use of DermDx results than without the use of DermDx results in the diagnosis of lesions suspicious of skin cancer, in comparison to the ground truth.
Conditions Studied
Interventions
- DEVICE DermDx
Study Locations (1)
South Carolina
- Remote - North Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2024-11-27 |
What the finished NCT06463860 record still lists
NCT06463860 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 462-participant average among 40 other Skin Cancer trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Skin Cancer appearing as the primary indexed condition, and to 1 intervention - of which DermDx is the first listed.
NCT06463860 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT06463860 about?
NCT06463860 is a clinical study titled "Multi-Center Study to Evaluate the Performance of DermDx for Primary Care Physicians in the Detection of Skin Cancers". The proposed study is a pivotal, multi-center retrospective reader study designed to determine whether the use of DermDx as a concurrent reading aid improves the performance of primary care physicians (PCPs) in diagnosing skin cancers.
What is the current status of trial NCT06463860?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2024-06-12. Estimated completion is 2024-11-27.
What conditions does trial NCT06463860 study?
This clinical trial studies the following conditions: Skin Cancer.
What interventions are being tested in trial NCT06463860?
The interventions under investigation include: DermDx (DEVICE).
Who is sponsoring clinical trial NCT06463860?
This trial is sponsored by MetaOptima Technology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06463860 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06463860's enrollment target sits among peer trials
81 19th of 40 higher than 22 of 40 other Skin Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
RECRUITING
-
Undergraduate Skin Cancer Prevention Trial
RECRUITING · Phase 3
-
Meloxicam in Mohs Micrographic Surgery
RECRUITING · Phase 4
-
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI